PT - JOURNAL ARTICLE AU - Parikh, Payal AU - Greenberg, Patricia AU - Halpert, Shmuel AU - Abrishami, Allison AU - Rabizadeh, Liora AU - Shayefar, Hannah AU - Tetelbaun, Lauren AU - Friedman, Dovid AU - Kaminetzky, Jeffrey TI - Mitigating the Severity of COVID-19 Illness in the Primary Care Patient Population through Early Identification and Close Monitoring of Underlying Comorbidities AID - 10.1101/2022.10.07.22280827 DP - 2022 Jan 01 TA - medRxiv PG - 2022.10.07.22280827 4099 - http://medrxiv.org/content/early/2022/10/10/2022.10.07.22280827.short 4100 - http://medrxiv.org/content/early/2022/10/10/2022.10.07.22280827.full AB - Purpose Prior studies have identified risk factors which prognosticate severity of SARS-CoV-2 illness among hospitalized patients. Since the majority of patients first present to ambulatory care sites, there is a need to identify early predictors of disease progression in this population.Methods This retrospective cohort study investigated the impact of underlying comorbid conditions on SARS-CoV-2 infection severity in the ambulatory setting. All patients who presented to a single federally qualified health center (FQHC) between March-May 2020 with a positive SARS-CoV-2 test were reviewed for inclusion. Patient demographics, symptomology, prior medical history, and outcomes were collected.Results 301 patients were included, with nearly equal numbers of patients with (n=151) and without (n=150) underlying comorbidities. Overall, 269 patients (89%) had a mild outcome and 32 patients (11%) had a severe outcome. Advanced age (OR: 9.4 [95% CI: 3.4-27.4], p < 0.001) and male gender (OR: 3.2 [95% CI: 1.2-9.8], p = 0.02) were significant predictors of severe outcomes. Additionally, every obesity category (1: BMI = 30.0–34.9; 2: BMI = 35–39.9; 3: BMI = 40.0+) was associated with more severe outcomes compared to non-obese (OR: 3.5, p = 0.05; OR: 5.2, p = 0.03; OR: 13.9, p = 0.01). Compared to an HbA1C < 6, an HbA1C of 7.1–8.0 showed a clinically significant association.Conclusion SARS-CoV-2 severity can be prognosticated in the ambulatory population by the presence and severity of pre-existing comorbidities. Early identification and risk stratification of these comorbidities will allow clinicians to develop plans for closer monitoring to prevent severe illness.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB from Rutgers, Robert Wood Johnson Medical School gave ethical approval for this work after review of the institutional requirements. Protocol number for IRB: Pro2020001234I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscriptARDSAcute Respiratory Distress SyndromeCOPDChronic Obstructive Pulmonary DiseaseEMRElectronic Medical RecordHbA1Cglycosylated hemoglobinBMIBody Mass Index